Ekso Bionics was upgraded to a Zacks Rank #2 (Buy) after analysts steadily raised EPS forecasts—Zacks' consensus for FY‑2025 remains negative at -$0.92 but has improved 21.4% over the past three months—placing EKSO in the top 20% of Zacks‑covered names for estimate revisions. Zacks argues that upward earnings revisions tend to prompt institutional re‑valuation and near‑term share appreciation, so the upgrade signals improving earnings momentum that could attract buying pressure. However, the company still operates from a negative earnings base, so further upside depends on continued estimate revisions and operational execution.
Zacks Investment Research upgraded Ekso Bionics (EKSO) to a Zacks Rank #2 (Buy) driven primarily by an upward trend in earnings estimates; the Zacks Consensus for fiscal 2025 EPS remains negative at -$0.92 but has risen 21.4% over the past three months. The upgrade places EKSO in the top 20% of Zacks-covered stocks for estimate revisions, signaling that analysts have materially improved near-term earnings expectations even though the company is still forecast to be loss-making for FY2025. Zacks highlights the empirical correlation between earnings estimate revisions and near-term stock price movement, noting that institutional investors use revised estimates to revalue fair value and can generate buying pressure when consensus improves. Key risks are that the current improvement is driven by analyst revisions rather than demonstrated profitability; further upside depends on continued positive revisions, operational execution, and any confirming quarterly results rather than the single upgrade alone, despite Zacks' historical claim that top-ranked stocks have outperformed on average.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
mildly positive
Sentiment Score
0.30
Ticker Sentiment
